PMID- 20117921
OWN - NLM
STAT- MEDLINE
DCOM- 20100805
LR  - 20181201
IS  - 1433-2981 (Electronic)
IS  - 0936-6555 (Linking)
VI  - 22
IP  - 4
DP  - 2010 May
TI  - Gene expression profiles of epidermal growth factor receptor, vascular 
      endothelial growth factor and hypoxia-inducible factor-1 with special reference 
      to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence 
      after rectal cancer surgery.
PG  - 272-80
LID - 10.1016/j.clon.2010.01.001 [doi]
AB  - AIMS: To establish a causal relationship between the gene expression profiles of 
      angiogenetic molecular markers, including epidermal growth factor receptor 
      (EGFR), vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1 
      (HIF-1), in rectal cancer and the local responsiveness to neoadjuvant 
      chemoradiotherapy and subsequent disease recurrence. MATERIALS AND METHODS: We 
      examined the pre-treatment tumour biopsies (n=40) obtained from patients with 
      rectal adenocarcinoma (clinical International Union Against Cancer stage ll/III) 
      who were scheduled to receive neoadjuvant 5-fluorouracil-based chemoradiotherapy 
      for EGFR, VEGF and HIF-1 expression by quantitative real-time polymerase chain 
      reaction. RESULTS: Responders (patients with significant tumour regression, i.e. 
      pathological grades 2/3) showed significantly lower VEGF, HIF-1 and EGFR gene 
      expression levels than the non-responders (patients with insignificant tumour 
      regression, i.e. pathological grades 0/1) in the pre-treatment tumour biopsies. 
      The elevated expression level of each gene could predict patients with a low 
      response to chemoradiation. During the median follow-up of all patients (41 
      months; 95% confidence interval 28-60 months), 6/40 (15%) developed disease 
      recurrence. Although local responsiveness to neoadjuvant chemoradiotherapy was 
      associated with neither local nor systemic disease recurrence, lymph node 
      metastasis and an elevated VEGF gene expression level were independent predictors 
      of systemic disease recurrence. The 3-year disease-free survival rates of the 
      patients with lower VEGF or EGFR expression levels were significantly lower than 
      those of patients with higher VEGF or EGFR expression levels. CONCLUSIONS: 
      Analysing VEGF expression levels in rectal cancer may be of benefit in estimating 
      the effects of neoadjuvant chemoradiotherapy and in predicting systemic 
      recurrence after rectal cancer surgery.
CI  - Copyright 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Toiyama, Y
AU  - Toiyama Y
AD  - Department of Gastrointestinal and Pediatric Surgery, Division of Reparative 
      Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, 
      Edobashi 2-174 Tsu, Mie 514-8507, Japan. ytoi0725@clin.medic.mie-u.ac.jp
FAU - Inoue, Y
AU  - Inoue Y
FAU - Saigusa, S
AU  - Saigusa S
FAU - Okugawa, Y
AU  - Okugawa Y
FAU - Yokoe, T
AU  - Yokoe T
FAU - Tanaka, K
AU  - Tanaka K
FAU - Miki, C
AU  - Miki C
FAU - Kusunoki, M
AU  - Kusunoki M
LA  - eng
PT  - Journal Article
DEP - 20100201
PL  - England
TA  - Clin Oncol (R Coll Radiol)
JT  - Clinical oncology (Royal College of Radiologists (Great Britain))
JID - 9002902
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (RNA, Messenger)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adenocarcinoma/genetics/metabolism/therapy
MH  - Aged
MH  - Antimetabolites, Antineoplastic/therapeutic use
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Combined Modality Therapy
MH  - ErbB Receptors/*genetics/metabolism
MH  - Female
MH  - Fluorouracil/*therapeutic use
MH  - Gene Expression Profiling
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*genetics/metabolism
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - *Neoadjuvant Therapy
MH  - Neoplasm Recurrence, Local/*genetics/metabolism/therapy
MH  - Oligonucleotide Array Sequence Analysis
MH  - RNA, Messenger/genetics/metabolism
MH  - Radiotherapy Dosage
MH  - Rectal Neoplasms/*genetics/metabolism/therapy
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A/*genetics/metabolism
EDAT- 2010/02/02 06:00
MHDA- 2010/08/06 06:00
CRDT- 2010/02/02 06:00
PHST- 2009/03/25 00:00 [received]
PHST- 2009/12/14 00:00 [revised]
PHST- 2009/12/15 00:00 [accepted]
PHST- 2010/02/02 06:00 [entrez]
PHST- 2010/02/02 06:00 [pubmed]
PHST- 2010/08/06 06:00 [medline]
AID - S0936-6555(10)00002-6 [pii]
AID - 10.1016/j.clon.2010.01.001 [doi]
PST - ppublish
SO  - Clin Oncol (R Coll Radiol). 2010 May;22(4):272-80. doi: 
      10.1016/j.clon.2010.01.001. Epub 2010 Feb 1.